253 related articles for article (PubMed ID: 26452132)
1. MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma.
Glover AR; Zhao JT; Gill AJ; Weiss J; Mugridge N; Kim E; Feeney AL; Ip JC; Reid G; Clarke S; Soon PS; Robinson BG; Brahmbhatt H; MacDiarmid JA; Sidhu SB
Oncotarget; 2015 Nov; 6(34):36675-88. PubMed ID: 26452132
[TBL] [Abstract][Full Text] [Related]
2. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
3. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.
Özata DM; Caramuta S; Velázquez-Fernández D; Akçakaya P; Xie H; Höög A; Zedenius J; Bäckdahl M; Larsson C; Lui WO
Endocr Relat Cancer; 2011 Oct; 18(6):643-55. PubMed ID: 21859927
[TBL] [Abstract][Full Text] [Related]
4. MiR-483-5p and miR-139-5p promote aggressiveness by targeting N-myc downstream-regulated gene family members in adrenocortical cancer.
Agosta C; Laugier J; Guyon L; Denis J; Bertherat J; Libé R; Boisson B; Sturm N; Feige JJ; Chabre O; Cherradi N
Int J Cancer; 2018 Aug; 143(4):944-957. PubMed ID: 29516499
[TBL] [Abstract][Full Text] [Related]
5. Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.
Salomon A; Keramidas M; Maisin C; Thomas M
Oncotarget; 2015 May; 6(13):11421-33. PubMed ID: 25823656
[TBL] [Abstract][Full Text] [Related]
6. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
Chabre O; Libé R; Assie G; Barreau O; Bertherat J; Bertagna X; Feige JJ; Cherradi N
Endocr Relat Cancer; 2013 Aug; 20(4):579-94. PubMed ID: 23756429
[TBL] [Abstract][Full Text] [Related]
7. Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment.
Bussey KJ; Demeure MJ
Future Oncol; 2009 Jun; 5(5):641-55. PubMed ID: 19519204
[TBL] [Abstract][Full Text] [Related]
8. The role of microRNAs in the adrenocortical carcinomas.
Yu X; Li Z
Tumour Biol; 2016 Feb; 37(2):1515-9. PubMed ID: 26671553
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-205 suppresses the growth of adrenocortical carcinoma SW-13 cells via targeting Bcl-2.
Wu Y; Wang W; Hu W; Xu W; Xiao G; Nie Q; Ouyang K; Chen S
Oncol Rep; 2015 Dec; 34(6):3104-10. PubMed ID: 26397843
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations.
Duregon E; Rapa I; Votta A; Giorcelli J; Daffara F; Terzolo M; Scagliotti GV; Volante M; Papotti M
Hum Pathol; 2014 Aug; 45(8):1555-62. PubMed ID: 24890943
[TBL] [Abstract][Full Text] [Related]
12. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis.
Tömböl Z; Szabó PM; Molnár V; Wiener Z; Tölgyesi G; Horányi J; Riesz P; Reismann P; Patócs A; Likó I; Gaillard RC; Falus A; Rácz K; Igaz P
Endocr Relat Cancer; 2009 Sep; 16(3):895-906. PubMed ID: 19546168
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal interplay of miR-497 and MALAT1 promotes tumourigenesis of adrenocortical cancer.
Hassan N; Zhao JT; Glover A; Robinson BG; Sidhu SB
Endocr Relat Cancer; 2019 Jul; 26(7):677-688. PubMed ID: 31085769
[TBL] [Abstract][Full Text] [Related]
14. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
15. Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review.
Xu C; Xu P; Zhang J; He S; Hua T; Huang A
Medicine (Baltimore); 2024 Jan; 103(4):e36908. PubMed ID: 38277554
[TBL] [Abstract][Full Text] [Related]
16. MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.
Patel D; Boufraqech M; Jain M; Zhang L; He M; Gesuwan K; Gulati N; Nilubol N; Fojo T; Kebebew E
Surgery; 2013 Dec; 154(6):1224-8; discussion 1229. PubMed ID: 24238045
[TBL] [Abstract][Full Text] [Related]
17. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
[TBL] [Abstract][Full Text] [Related]
18. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
Ren L; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang J
J Transl Med; 2022 Oct; 20(1):444. PubMed ID: 36184616
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA UCA1 promoted the growth of adrenocortical cancer cells via modulating the miR-298-CDK6 axis.
Guo N; Sun Q; Fu D; Zhang Y
Gene; 2019 Jun; 703():26-34. PubMed ID: 30935924
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.
Ibrahim AF; Weirauch U; Thomas M; Grünweller A; Hartmann RK; Aigner A
Cancer Res; 2011 Aug; 71(15):5214-24. PubMed ID: 21690566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
